Sequoia Financial Advisors LLC Sells 10,990 Shares of Bruker Corporation (NASDAQ:BRKR)

Sequoia Financial Advisors LLC lessened its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 27.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 28,609 shares of the medical research company's stock after selling 10,990 shares during the period. Sequoia Financial Advisors LLC's holdings in Bruker were worth $1,194,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in BRKR. London Co. of Virginia grew its position in shares of Bruker by 78.4% during the 4th quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after acquiring an additional 1,843,294 shares during the period. Brown Advisory Inc. lifted its stake in Bruker by 10.1% in the fourth quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company's stock valued at $118,806,000 after purchasing an additional 185,912 shares during the last quarter. Geode Capital Management LLC grew its holdings in Bruker by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock valued at $118,081,000 after purchasing an additional 20,273 shares during the period. FIL Ltd grew its holdings in Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after purchasing an additional 1,420,102 shares during the period. Finally, Sculptor Capital LP increased its position in Bruker by 484.1% in the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock worth $100,476,000 after buying an additional 1,420,569 shares during the last quarter. Institutional investors own 79.52% of the company's stock.

Insider Buying and Selling at Bruker

In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the company's stock in a transaction that occurred on Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 27.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on BRKR shares. Barclays dropped their price target on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. The Goldman Sachs Group lowered their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. UBS Group dropped their price objective on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus reduced their target price on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Finally, Wells Fargo & Company lowered their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Bruker presently has a consensus rating of "Hold" and a consensus price target of $52.89.

Bruker Price Performance

BRKR stock traded down $0.04 during mid-day trading on Thursday, reaching $42.42. 1,207,758 shares of the company traded hands, compared to its average volume of 1,704,092. The company has a fifty day moving average price of $38.81 and a 200-day moving average price of $46.24. Bruker Corporation has a 52-week low of $34.10 and a 52-week high of $72.94. The company has a market capitalization of $6.43 billion, a P/E ratio of 81.58, a P/E/G ratio of 2.81 and a beta of 1.18. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. The company had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. Bruker had a net margin of 2.31% and a return on equity of 19.47%. Bruker's revenue was up 11.0% compared to the same quarter last year. During the same period last year, the business earned $0.53 earnings per share. As a group, analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 annualized dividend and a dividend yield of 0.47%. Bruker's payout ratio is currently 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.